Schalla W, Schorning S
Cutaneous Studies International (CSI), Freiburg, FRG.
Skin Pharmacol. 1991;4(3):191-204. doi: 10.1159/000210949.
The topical anti-inflammatory activity of potent and very potent corticoids was studied in normal and inflamed skin using the vasoconstriction assay and tuberculin-induced inflammation in four double-blind intraindividual comparison trials. Instrumental techniques in addition to visual scores and several time points were applied to get better insight into the reliability of the models and the sensitivity of the different variables. Beta-methasone-17-valerate and two concentrations of prednicarbate were used as potent corticoids, clobetasol-17-propionate, betamethasone-17,21-dipropionate and different biopharmaceutical forms of desoximetasone (DOM) as very potent corticoids. Visual scores, the reactive skin hyperemia after arterial occlusion and skin colorimetry were used to quantify vasoconstriction; erythema scores, surface area of infiltration and changes in skin colorimetry, skin blood flow and skin temperature for the tuberculin reaction. The time courses of blanching (n = 20) and of the tuberculin reaction (n = 10) were described by orthogonal polynomials and the coefficients were statistically analyzed by nonparametric tests, the discriminative variables in tuberculin inflammation in addition by the parametric multiple analysis of variance. Important differences in the release rates of corticoids demand several assessment times and not just one as often used. The potency ranking may otherwise be misleading. In general, ointments released corticoids slowlier than the cream which in turn liberated slowlier than the gels. The DOM gel declined rapidly after an apparent peak at 5.5 h in terms of its blanching effect, but was nevertheless comparable after once-daily application to other very potent corticoids in its activity against delayed-type inflammation. Such differences may explain discrepancies found for some corticoid preparations between their blanching response and clinical efficacy. The more potent a corticoid the more the erythema is reduced, the less pronounced the cell infiltration and the more delayed the peak seems from 24 to 48 h in the tuberculin reaction. The inflammatory response is diminished in the following manner: very potent greater than potent corticoids; erythema greater than infiltration. Visual scores were the most reliable parameters in normal and inflamed skin and they correlated well with skin colorimetry which shows greater variability. Reactive hyperemia after arterial occlusion gave poor results in terms of ranking in the vasoconstriction assay as did resting skin blood flow in inflamed skin. Changes in the temperature of inflamed skin are sensitive enough to discriminate the active drugs from the controls, but have a somewhat different time course, reflecting perhaps a higher impact of the amount of mediator release in the early phase relative to the cell invasion in the later phase.
在四项双盲个体内比较试验中,使用血管收缩试验和结核菌素诱导的炎症反应,在正常皮肤和炎症皮肤中研究了强效和超强效皮质类固醇的局部抗炎活性。除视觉评分和多个时间点外,还应用了仪器技术,以便更好地了解模型的可靠性和不同变量的敏感性。使用倍他米松 - 17 - 戊酸酯和两种浓度的泼尼卡酯作为强效皮质类固醇,丙酸氯倍他索、倍他米松 - 17,21 - 二丙酸酯以及不同生物药剂形式的去氧米松(DOM)作为超强效皮质类固醇。视觉评分、动脉闭塞后的皮肤反应性充血和皮肤比色法用于量化血管收缩;红斑评分、浸润面积以及结核菌素反应中皮肤比色法、皮肤血流和皮肤温度的变化用于评估。通过正交多项式描述变白(n = 20)和结核菌素反应(n = 10)的时间进程,并通过非参数检验对系数进行统计分析,对于结核菌素炎症中的判别变量,还通过参数方差分析进行分析。皮质类固醇释放速率的重要差异需要多个评估时间,而不是像通常那样只进行一次评估。否则,效价排名可能会产生误导。一般来说,软膏释放皮质类固醇的速度比乳膏慢,而乳膏又比凝胶慢。DOM凝胶在变白效应方面在5.5小时出现明显峰值后迅速下降,但其每日一次给药后在对抗迟发型炎症的活性方面与其他超强效皮质类固醇相当。这种差异可能解释了一些皮质类固醇制剂在变白反应和临床疗效之间存在的差异。皮质类固醇越强,红斑减少越明显,细胞浸润越不明显,在结核菌素反应中从24小时到48小时的峰值出现越延迟。炎症反应以以下方式减弱:超强效大于强效皮质类固醇;红斑大于浸润。视觉评分是正常皮肤和炎症皮肤中最可靠的参数,并且与变异性更大的皮肤比色法相关性良好。在血管收缩试验中,动脉闭塞后的反应性充血在排名方面结果不佳,炎症皮肤中的静息皮肤血流也是如此。炎症皮肤温度的变化足够敏感,能够区分活性药物和对照,但具有 somewhat different time course,这可能反映了早期介质释放量相对于后期细胞侵袭的更高影响。 (注:原文中“somewhat different time course”未准确翻译,因不清楚具体含义,暂保留英文表述)